Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reverses Stance On Bioequivalence Standards For Mesalamine

Executive Summary

FDA believes that comparative pharmacokinetic studies, instead of comparative clinical endpoint studies, are best for determining bioequivalence of extended- or delayed-release mesalamine products - a reversal of its previous position

You may also be interested in...

FDA Bioequivalence Guidance Expands Crossover Designs For ANDA Studies

Guidance “will be especially useful” for planning studies to support postapproval ANDA changes, the agency notes.

Pediatric Bioequivalence Studies Are Unnecessary, FDA Says In Rejecting Nycomed Petition

Nycomed had sought additional approval requirements for generic versions of its atopic dermatitis lotion Cutivate.

Generics For Risperdal Consta Need Multi-Dose Testing, J&J Argues

Citizen petition tells FDA not to worry about bioequivalence tests in fasting patients, but focus on the product's three-stage release characteristics.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts